about
Large extent of disorder in Adenomatous Polyposis Coli offers a strategy to guard Wnt signalling against point mutationsIdentification of HEXIM1 as a positive regulator of p53MDM4 binds ligands via a mechanism in which disordered regions become structuredChemical Variations on the p53 Reactivation ThemeApoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategiesModulation of Protein-Protein Interactions for the Development of Novel TherapeuticsAntimitotic drugs in the treatment of cancermiRNA interventions serve as 'magic bullets' in the reversal of glioblastoma hallmarksDirect and Propagated Effects of Small Molecules on Protein-Protein Interaction NetworksProtein Folding and Mechanisms of ProteostasisGenomic profiling of small-cell lung cancer: the era of targeted therapiesClinical implications of the molecular genetics of chronic lymphocytic leukemiaEndogenous retroviruses and the development of cancerThe role of the endosomal sorting complexes required for transport (ESCRT) in tumorigenesisProtein-protein interaction networks: probing disease mechanisms using model systemsSmall molecule compounds targeting the p53 pathway: are we finally making progress?Identification of novel p53 pathway activating small-molecule compounds reveals unexpected similarities with known therapeutic agentsElucidation of Ligand-Dependent Modulation of Disorder-Order Transitions in the Oncoprotein MDM2C-terminal substitution of MDM2 interacting peptides modulates binding affinity by distinctive mechanismsSystematic Mutational Analysis of Peptide Inhibition of the p53–MDM2/MDMX InteractionsLimitations of Peptide Retro-inverso Isomerization in Molecular MimicryA Left-Handed Solution to Peptide Inhibition of the p53-MDM2 InteractionD-peptide inhibitors of the p53–MDM2 interaction for targeted molecular therapy of malignant neoplasmsActivation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerizationThe p53 cofactor Strap exhibits an unexpected TPR motif and oligonucleotide-binding (OB)-fold structureSmall molecule induced reactivation of mutant p53 in cancer cellsHalogen-Enriched Fragment Libraries as Leads for Drug Rescue of Mutant p53In Vivo Activation of the p53 Tumor Suppressor Pathway by an Engineered CyclotideTransient Protein States in Designing Inhibitors of the MDM2-p53 InteractionAn Ultrahigh Affinity d -Peptide Antagonist Of MDM2Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical DevelopmentDiscovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical DevelopmentThe structure of an MDM2-Nutlin-3a complex solved by the use of a validated MDM2 surface-entropy reduction mutantThe p53 pathway as a target in cancer therapeutics: obstacles and promiseStructural basis of how stress-induced MDMX phosphorylation activates p53Double Strain-Promoted Macrocyclization for the Rapid Selection of Cell-Active Stapled Peptidesp53 Acetylation: Regulation and ConsequencesPP2A: The Wolf in Sheep's Clothing?Ral GTPase down-regulation stabilizes and reactivates p53 to inhibit malignant transformationA versatile platform to analyze low-affinity and transient protein-protein interactions in living cells in real time
P2860
Q21559553-6F02A73A-D95A-4C80-9054-B6E71EB423CFQ24297975-8D271E76-8440-4901-AC15-F5DE9C2754A6Q24316349-981948F3-85A7-4096-8896-4291B451E05EQ26749008-8A0BD0B9-9C8F-42D1-B8CE-4F879B5344C6Q26750639-AE5FA6CC-F66F-409E-B9ED-354C81445C69Q26775356-7BEBD710-96E5-4516-A1BE-DC1B038196CBQ26777317-6C80A123-B0DB-4E80-A8CB-BA0A02A48412Q26781836-591E173B-0B87-4F9F-B10E-847BB6449C68Q26784027-EA401450-BD80-41A0-82DC-E52B04B63061Q26801512-09166001-660A-4F86-87DC-BB0EA64AA790Q26826915-9F2C55B6-B40C-4576-AE27-1E6CA9B74B6CQ26830955-935ECD25-E2A9-48E5-B78C-50635923179CQ26852000-26313711-4C17-4C04-8D35-A7900B9B9EA8Q26864942-08FD7EA5-42B4-4492-9E57-2418DEEF26DBQ27027554-B98C30F8-24E4-4CFF-9580-5DC963AA23CAQ27027835-BF3E6A04-F461-4396-A06E-3754125B0AE2Q27318801-53544E3E-14DB-4D32-A997-4FC0D3E7408DQ27318807-1A13D595-B9E7-4B23-890A-24AC4FB56BABQ27322545-2DB16587-61BF-4B61-9CA9-EE359B4F7763Q27660219-A2CBA2E2-8B9E-4D5E-8C02-779CEB6F7A7EQ27660480-7FE6A5C8-838D-4E87-8565-E9449A7DED17Q27661400-148D31DD-1D9B-44E1-B6A1-09A069894064Q27663612-5CCC7F5B-B70B-41DC-9CAC-C8B3CFBB1ADBQ27670558-2DF13E52-897E-4F06-BEC2-EA8E8D4C53D2Q27677458-9CE5A81D-0DB2-488A-9F32-6260336FDE7AQ27677872-2D43BAD1-B452-48A7-9933-133822562B77Q27678152-46513B3B-1D9E-47F7-9627-2A21C2D6B086Q27679062-CCE78576-4DB0-4D16-84C1-08A092E1983AQ27680560-2FE67F98-D8F0-4914-92F3-82B519AC8DD3Q27681154-D569A9D1-A307-43AD-BF66-4BAD851C3C17Q27684199-E8449D10-2907-4C22-B9A4-01B34077DA0AQ27684218-ECC9F7EA-E1CC-403A-A26B-0B0AB39CE001Q27685287-78EDD77E-A10E-4913-B225-2067E1FD65E3Q27690770-B8467849-7227-4FE8-8CDC-CB9D0EE547AAQ27701526-C0163469-B54C-44D0-B049-8C1B534B2DEFQ27703615-EBCA8EB2-52B1-4DF1-BD71-E9F1831D5DCFQ28085076-A7EB2B78-A2C6-4B80-A221-DA677A5A43C2Q28088747-E90F8D68-EB2B-4D98-A4D9-A71B0E32F164Q28247699-334156C0-9FA4-4321-86A0-D96BB2D01458Q28253043-D48C7C17-7D83-4786-9796-B3BA58739160
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Awakening guardian angels: drugging the p53 pathway.
@ast
Awakening guardian angels: drugging the p53 pathway.
@en
type
label
Awakening guardian angels: drugging the p53 pathway.
@ast
Awakening guardian angels: drugging the p53 pathway.
@en
prefLabel
Awakening guardian angels: drugging the p53 pathway.
@ast
Awakening guardian angels: drugging the p53 pathway.
@en
P2093
P2860
P356
P1476
Awakening guardian angels: drugging the p53 pathway.
@en
P2093
Chandra S Verma
Christopher J Brown
David P Lane
Sonia Lain
P2860
P2888
P304
P356
10.1038/NRC2763
P407
P50
P577
2009-12-01T00:00:00Z